PhD in Cell Biology, 2004, University of Alabama at Birmingham, AL, USA
MS in Cell Biology, 1995, Beijing Medical University, Beijing, China
BS in Cell Biology, 1992, Wuhan University, Wuhan, China
1. Chen S#, Jiang X#, Gewinner CA#, Asara JM, Cai C, Cantley LC , and Balk SP. (2013) Tyrosine kinase Bmx phosphorylates phosphotyrosine primed motif regulating multiple tyrosine kinases. Sci Signal 6:ra40 (#：Co-first author)
2. Jiang X, Su L, Zhang Q, He C, Zhang Z, Yi P, and Liu J. (2012). GABAB receptor complex as a potential target for tumor therapy. J Histochem Cytochem 60: 269-279.
3. Jiang X, Chen S, Asara JM, and Balk SP. (2010). Phosphoinositide 3-kinase pathway activation in phosphatase and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem. 285: 14980-14989.
4. Cai C, Portnoy DC, Wang H, Jiang X, Chen S, and Balk SP. (2009). Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2. Cancer Res. 69: 5202-5209.
5. Hur W, Velentza Q, Kim S, Flatauer L, Jiang X, Valente D, Mason DE, Suzuki M, Larson B, Zhang J, Zagorska A, DiDonato M, Nagle A, Warmuth M, Balk SP, Peters EC, and Gray NS. (2008). Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorg Med Chem Lett. 18: 5916-5919.
6. Jiang X, Borgesi R, Kaur R, and Balk SP. (2007). Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, EGF receptor, and ErbB3 in prostate cancer cell. J Biol Chem. 282: 32689-32698.
7. Jang MH, Herber DM, Jiang X, Nandi S, Dai XM, Zeller G, Stanley ER, and Kelley VR. (2006). Distinct in vivo roles of colony-stimulating factor-1 isoforms in renal inflammation. J Immunol. 177: 4055-4063.
8. Jiang X, Multhaupt HAB, Schaefer L, Schaefe RM, and Couchman JR. (2004). Essential contribution of tumor-derived perlecan to epidermal tumor growth and angiogenesis. J Histochem Cytochem. 52: 1575-1590.
9. Jiang X and Couchman JR. (2003). Perlecan and tumor angiogenesis. J Histochem Cytochem. 51: 1393-1410.
10. Tapanadechopone P, Tumova S, Jiang X, and Couchman JR. (2001). Epidermal transformation leads to increased perlecan synthesis with heparin-binding growth factor affinity. Biochem J. 355: 517-527.